PRAXIS PRECISION MEDICINES, INC. (PRAX) - GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - PRAXIS PRECISION MEDICINES INC

Explicit Guidance:

• Financial Runway: Updated cash balance of $1.3 billion, extending the operational runway into 2028 to cover upcoming launches and pipeline advancement.
• NDA Submission Timeline: Expectation to announce the readiness date for submitting the NDA for the RELUTRIGINE (MREL) indication on Thursday (immediate future relative to transcript).
• Investor Day: Scheduled for an upcoming date in New York with a webcast option to discuss strategic updates.

Business-Segment Outlook:

• Ulexacultamide Hydrochloride (ELIXIR):
  • Approval & Launch: High certainty of approval with PDUFA target in January; immediate launch execution anticipated upon approval letter receipt.
  • Labeling: FDA and company are well-aligned on labeling; no negative impacts on efficacy assessments across subgroups expected. A "very likely" titration protocol will be included on the label to manage discontinuation rates.
  • Scheduling: Strongly favoring a non-scheduled (Schedule IV or V) classification; currently awaiting definitive decision from HHS/GSA, though supply chain logistics are prepared for a potential controlled substance status.
• Relutrigine (RELUTRIGINE):
  • Review Status: NDA under review with PDUFA date of December 27; FDA discussions are "a little behind" relative to ELIXIR due to information requests, but no open questions are expected to block approval.
  • Indication Strategy: The RELUTRIGINE Phase 3 (EMERALD) study is sufficient for the NDA submission for the current indication.
• Retrogene:
  • Clinical Trials: POWER2 trial is active; POWER3 trial initiation expected next year (following key opinion leader feedback).
  • Pipeline Readout: Data readout for the RELUTRIGINE MREL study expected later this week/Thursday, with a focus on open-label data strength and seizure burden reduction in fragile populations.

Market and Competitive Outlook:

• Essential Tremor Market: Targeting the broad adult population living with essential tremor; no identified subgroups with reduced efficacy.
• SCN2A/8A Market: Projected US addressable market of 30x the size of the current small patient populations (5-10k), representing significant unfulfilled need.
• Pricing Strategy: Plans to move from "opinion" to "data-driven" pricing discussions; intends to demonstrate value to eliminate pricing debates and prevent future price reductions despite market expansion.
• Discontinuation Rates: Targeting to guide physicians and patients to reduce discontinuation rates, aiming to align with the ~70% improvement in retention seen in earlier studies (Essential 1) versus Essential 3.

Macro / Industry Outlook:

• Regulatory Environment: FDA review timelines are subject to staffing changes (e.g., lead reviewer retirements), which may cause minor delays but are not anticipated to negatively impact approval outcomes.
• Scheduling Impact: Anticipated potential for a 3-month delay in launch if a controlled substance schedule is assigned, though the company is prepared to execute the launch immediately upon approval regardless of scheduling status.

Strategic Initiatives:

• Pipeline Expansion: Advancing Retrogene POWER3 study to optimize study design; initiating MREL readout to support the RELUTRIGINE commercial launch.
• Data Validation: Commitment to rigorous data quality control (QCing every form/field) for the MREL study to ensure the highest quality readout and prevent post-announcement delays.
• Commercial Readiness: Finalizing launch preparations for ELIXIR to occur immediately upon NDA approval, regardless of scheduling finalization.

Risks and Headwinds to Outlook:

• Labeling Uncertainty: Final text for labeling (specifically titration and discontinuation mitigation strategies) remains undetermined pending FDA finalization.
• Scheduling Decision: Final determination on drug scheduling by HHS/GSA could impact supply chain logistics and potentially delay the initial shipment window by up to 3 months.
• Review Timelines: The RELUTRIGINE review is slightly behind schedule compared to ELIXIR due to pending information requests, introducing a minor layer of uncertainty regarding the exact approval date before the PDUFA.
• Study Data Readout Timing: MREL data readout date is intentionally vague (window between "now and end of year") to account for logistical documentation delays, though this does not reflect negative clinical outcomes.

Management Tone on the Future:

• Confidence: Extremely high confidence in the approval of both ELIXIR and RELUTRIGINE; described ELIXIR discussions as having a "very high certainty" of approval.
• Forward-Looking Stance: Aggressive on value demonstration; management expresses frustration with pricing debates and intends to use data to justify pricing power.
• Strategic Patience: Willing to delay MREL data readout for quality assurance and POWER3 study for optimal design, prioritizing the strength of the commercial package over immediate data release speed.

Miscellaneous:

• Patient Demographics: SCN1A patient inclusion in the MREL study is low single-digit percentage, mitigating historical efficacy concerns.
• Study Design: MREL study utilized a 4-week placebo window (vs. longer in previous studies) to address safety in fragile populations; significant open-label data accumulation is a key differentiator.